Generic Name and Formulations:
Levobunolol HCl 0.5%; oph. soln; contains benzalkonium chloride.
1–2 drops of 0.5% 1–2 times daily.
Bronchial asthma. Severe COPD. Sinus bradycardia. 2nd- or 3rd-degree AV block. Overt cardiac failure. Cardiogenic shock.
Diabetes. Hyperthyroidism. Diminished pulmonary function. Angle-closure glaucoma. Myasthenia. Withdraw gradually before surgery. Discontinue at first sign of cardiac failure. Pregnancy (Cat.C). Nursing mothers.
Additive effects with systemic β-blockers, reserpine. Mydriasis with epinephrine.
Systemic absorption (bronchospasm, cardiac failure), transient ocular burning, stinging, blepharoconjunctivitis, bradycardia, hypotension, iridocyclitis, headache, transient ataxia, dizziness, lethargy, urticaria, pruritus, decreased corneal sensitivity.
Soln 0.5%— 5mL, 15mL